THE SCIENCE
Sermorelin research: the mechanism, the human trials, and the body-composition evidence
How GHRH(1-29) signals the pituitary, what the GH/IGF-1 studies measured, and how sermorelin compares to its cousins — every figure cited.
Before the details
Here is the whole sermorelin story in plain words before we go deep. Your brain naturally makes a hormone called GHRH (growth hormone-releasing hormone) that tells your pituitary gland to release growth hormone (GH). Sermorelin is a lab copy of the active part of GHRH — its first 29 amino acids — so it does the same job: it asks your pituitary to release your own GH. It does not add growth hormone from outside. The cleanest human evidence is in children who weren't growing and in short studies that measured GH and IGF-1 in older men. The body-fat results people want are mostly from a close relative, tesamorelin, not from sermorelin trials in healthy adults. Below: what sermorelin is, exactly how it signals, what each trial measured, and how it stacks up against ipamorelin, tesamorelin, and direct GH.
What is sermorelin
Sermorelin is a synthetic 29-amino-acid peptide — the amino-terminal 1-29 fragment of human GHRH, which is the shortest piece that keeps GHRH's full activity at its receptor. (Amino acids are the building blocks of proteins; a peptide is a short chain of them.) Its acetate salt has the formula C149H246N44O42S, a molecular weight near 3358 daltons, and CAS number 86168-78-7. Chemically it mimics endogenous GHRH — the body's own version — which loses output as we age, one reason GH naturally falls over the decades [6]. The 2025 Nature Reviews Endocrinology synthesis places sermorelin within the broader family of GHRH agonists and antagonists, mapping the receptor signaling and the GH/IGF-1 axis it feeds [9].
Sermorelin peptide
As a sermorelin peptide, the molecule's value is its precision: it acts only at the GHRH receptor on the pituitary's growth-hormone-making cells (somatotrophs), switching on the cAMP/PKA relay inside the cell to trigger a pulse of GH and to support the cells' upkeep over time [1][9]. Because the signal flows through the body's normal circuit, the natural brakes stay intact — somatostatin and IGF-1 feedback keep GH from running away, which preserves the pulsing on-off pattern that distinguishes a secretagogue from injected GH [6]. The native peptide clears the blood fast — on the order of 10-12 minutes after an intravenous dose — yet a single dose keeps GH elevated for about 3 hours [4]. That short life is exactly why chemists built longer-lasting analogs.
The human GH and IGF-1 trials
The most direct human data are decades old and consistent. In a multicenter trial of prepubertal growth-hormone-deficient children, once-daily subcutaneous sermorelin accelerated linear growth — first-year height velocity rose from about 4.1 cm/year toward 7-8 cm/year — without excessive IGF-1 [2]. In healthy older men (mean age 68), 0.5 mg and 1 mg twice daily for 14 days produced dose-related rises in 24-hour GH and IGF-1; after the high dose, their GH/IGF-1 parameters no longer differed from young men, with no change in fasting glucose [3]. A pharmacokinetic study in 30 healthy men found GHRH(1-29) triggered GH release at intravenous doses as low as 0.25 mcg/kg, peaking around 1-2 mcg/kg, while the nasal route reached only 3-5% bioavailability [4]. Together these establish the core effect — sermorelin reliably raises the body's own GH and IGF-1 — and explain why injection, not pills, is the studied route.
The body-composition and metabolic evidence
The metabolic case for the GHRH-analog class is real, but most of it sits one step from sermorelin itself. Pulsatile GH helps regulate the breakdown of stored fat in fasting humans, so restoring that pulse has a clear metabolic rationale [11]. Obesity blunts the GH response to GHRH, and that blunting tracks with cardiometabolic risk — meaning the people most interested in body composition often have the most suppressed signal to begin with [10]. When researchers gave the stabilized GHRH analog tesamorelin to older adults for 20 weeks, percent body fat fell about 7.4% and IGF-1 rose 117% within the normal range [7]; a randomized trial in adults with obesity and reduced GH found body-composition effects from the same approach [8]. A men's-health review frames GH secretagogues as a tool for body composition beyond testosterone-based therapy [12]. The honest reading: the class moves body composition; dedicated long-term sermorelin trials for fat loss in healthy adults are the missing piece [5].
Sermorelin vs ipamorelin
Sermorelin vs ipamorelin is a comparison of two different doorways to the same goal. Sermorelin is a GHRH analog — it works at the GHRH receptor, copying the brain's natural 'release GH' signal [1]. Ipamorelin belongs to a separate family, the growth-hormone-releasing peptides (GHRPs), which act at the ghrelin/GHS receptor — a different lock entirely [9]. Because they hit different receptors, researchers note the two pathways can be complementary in principle. This site reports on sermorelin; ipamorelin is named only as a research comparator, and no head-to-head efficacy claim is made here beyond the mechanism distinction.
Recent reviews and the regenerative frontier
The newest literature is largely synthesis and early signals rather than new human fat-loss trials. The 2025 Nature Reviews Endocrinology review consolidates GHRH biology across health and disease [9], and 2025 reviews in Reviews in Endocrine and Metabolic Disorders examine GHRH in diabetes and metabolism and within central and peripheral GH/IGF-1 regulation [13][14]. On the preclinical edge, a GHRH-receptor agonist improved outcomes in a mouse model of cardiometabolic heart failure, extending the regenerative signal for GHRH-receptor activation [15] — a hypothesis-generating animal result, not human evidence. These belong on the frontier, clearly labeled as such, not in the proven column.